{"id":2637,"date":"2019-03-01T12:03:00","date_gmt":"2019-03-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/protonenpumpenhemmer-zur-praevention-gastrointestinaler-blutungen-unter-oralen-antikoagulanzien"},"modified":"2019-03-01T12:03:00","modified_gmt":"2019-03-01T11:03:00","slug":"protonenpumpenhemmer-zur-praevention-gastrointestinaler-blutungen-unter-oralen-antikoagulanzien","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/protonenpumpenhemmer-zur-praevention-gastrointestinaler-blutungen-unter-oralen-antikoagulanzien","title":{"rendered":"Protonenpumpenhemmer zur Pr\u00e4vention gastrointestinaler Blutungen unter oralen Antikoagulanzien?"},"content":{"rendered":"<p>Gastrointestinale Blutungen (GIB), insbesondere im oberen Gastrointestinaltrakt, sind eine h\u00e4ufige und potenziell gef\u00e4hrliche Nebenwirkung oraler Antikoagulanzien (OAK). In den gro\u00dfen Phase-III-Studien zur Zulassung der direkten oralen Antikoagulanzien (DOAK) bei Vorhofflimmern waren starke GIB unter Rivaroxaban (Xarelto\u00ae), Dabigatran (Pradaxa\u00ae, 150 mg) und Edoxaban (Lixiana\u00ae) h\u00e4ufiger als unter dem Vitamin-K-Antagonisten (VKA) Warfarin und unter Apixaban (Eliquis\u00ae) etwa [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gastrointestinale Blutungen (GIB), insbesondere im oberen Gastrointestinaltrakt, sind eine h\u00e4ufige und potenziell gef\u00e4hrliche Nebenwirkung oraler Antikoagulanzien (OAK). In den gro\u00dfen Phase-III-Studien zur Zulassung der direkten oralen Antikoagulanzien (DOAK) bei Vorhofflimmern waren starke GIB unter Rivaroxaban (Xarelto\u00ae), Dabigatran (Pradaxa\u00ae, 150 mg) und Edoxaban (Lixiana\u00ae) h\u00e4ufiger als unter dem Vitamin-K-Antagonisten (VKA) Warfarin und unter Apixaban (Eliquis\u00ae) etwa [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1322,2305,1314,1312,2068,1328,1327,111,291,115,114,2304,136],"class_list":["post-2637","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-apixaban","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-neue-orale-antikoagulanzien","tag-noak","tag-omeprazol","tag-pantoprazol","tag-protonenpumpen-hemmer","tag-protonenpumpenhemmer","tag-rivaroxaban","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2637"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2637\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}